Immuron Receives AUD $306,154 R&D Tax Concession Refund
January 17 2022 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the prevention and treatment of gut
mediated pathogens, is pleased to announce that under the
Australian Government’s Research and Development Income Tax
Concession incentive program, the Company has received a cash
refund of AUD $306,154 for eligible research and development
expenditure incurred during the 2021 Financial Year.
This release has been authorized by the
directors of Immuron Limited.
COMPANY
CONTACT:Dr Jerry
Kanellos, Ph.D.Chief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
US INVESTOR CONTACTDave Gentry,
CEORedChip Companies
Inc.+1-407-491-4498dave@redchip.com |
|
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious
diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024